23 results about "Serum glucose" patented technology

This invention discloses the application of IKK inhibitors in the preparation of drugs to restore pancreatic islet function. IKK inhibitors can effectively improve the problem of pancreatic β-cell differentiation defects, significantly increase the number of pancreatic β-cells, enhance the insulin secretion capacity of islet cells, and specifically upregulate the expression of key functional genes of pancreatic β-cells such as INS and NKX6.1 genes, thus repairing pancreatic islet function damage. This solves the technical problem that current treatments for type 1 diabetes can only replace insulin and relieve blood sugar symptoms, but cannot fundamentally repair pancreatic islet function. IKK inhibitors can be used to prepare drugs for the treatment of type 1 diabetes, providing a new approach for the clinical treatment of type 1 diabetes and possessing extremely high clinical translational value.

The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and / or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and / or triglycerides, so can be used to treat diabetes, obesity and / or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

This invention provides a hypoglycemic subspecies of Bifidobacterium animalis (Liver) and its applications. The Bifidobacterium animalis (Liver) subspecies is named Tianshan-1 and is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 35821 on September 5, 2025. Cell experiments show that Tianshan-1 significantly promotes the secretion of GLP-1 from human colorectal adenocarcinoma cells NCI-H716 and upregulates GCG gene expression levels. Animal experiments confirm that this strain significantly increases serum GLP-1 concentration in diabetic mice and reduces fasting blood glucose and glycated hemoglobin levels, with no significant difference in hypoglycemic effect compared to the positive control. This strain is a food-grade safe probiotic with a clear mechanism of action and stable effects, providing a safe, long-lasting, and industrially viable new probiotic resource for diabetes prevention and treatment, with broad application prospects.

This invention relates to peptide complexes with anti-diabetic activity and their uses. The peptide complexes of this invention promote cellular glucose uptake, inhibit insulin resistance signaling, promote insulin sensitivity signaling, and inhibit apoptosis of pancreatic β-cells, which are insulin-producing cells, thereby exhibiting a blood glucose-lowering effect. Furthermore, this invention also relates to peptides with anti-diabetic and anti-obesity activities and their uses. The peptides of this invention have activities that inhibit insulin resistance signaling, promote insulin sensitivity signaling, and promote lipolysis in adipocytes.

This invention discloses a DPP-IV inhibitory peptide from tilapia skin fermented with Aspergillus oryzae, its preparation method, and its applications, belonging to the field of food-derived bioactive peptide development technology. Using tilapia skin as raw material, this invention employs a combined process of acid-base pretreatment, warm water extraction, Aspergillus oryzae fermentation, gel column chromatography, and semi-preparative liquid chromatography to obtain tilapia skin bioactive peptides with high DPP-IV inhibitory activity. The amino acid sequences are AAGVGEF, GIADRMQ, and KPLRLPL, respectively. These three inhibitory peptides exhibit good DPP-IV inhibitory activity and can be used to develop health products or pharmaceuticals for regulating blood sugar.

The present application discloses the use of FGF21 / GLP-1 fusion proteins in the preparation of a medicament for preventing and / or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21 / GLP-1 fusion proteins of the present application are effective in treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia, and in particular, can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, or increase at least one of adiponectin, insulin sensitivity, and beta-cell function in the subject.

The application relates to the field of biological medicines and provides a GLP-1, GIP and GCG receptor triple agonist and application thereof, and relates to a peptide compound with formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X1X2X3 is H-Aib-H, Y-Aib-Q or Y-Ac3c-Q; X17 is Q or K; X18X19 is YA, YQ or AQ; X20 is Aib or Ac3c; X21 is A, D, E or R; X23 is V or I; X24X25 is NW, QR, EY, RY, RH or RW; X28 is E, R or A; X40 is K or is not present; and the C-terminal amino acid is optionally amidated into a C-terminal primary amide. The peptide compound has the effects of reducing weight and controlling blood sugar.

The present application relates to a sustained-release pharmaceutical composition of GLP-1 receptor agonist and a preparation method thereof. The composition comprises 0.05-0.5 wt% active ingredient, 45-85 wt% sustained-release agent, and 15-55 wt% viscosity reducer, or comprises 0.05-0.5 wt% active ingredient and 45-99.95 wt% thermal sensitive sustained-release agent. The active ingredient is GLP-1 receptor agonist, the sustained-release agent is polyorthoester, and the viscosity reducer is preferably glycerate compound. The present application also provides a pharmaceutical combination product comprising the sustained-release pharmaceutical composition, and application of the composition in treating metabolic related diseases. The sustained-release pharmaceutical composition has significantly improved pharmacokinetic characteristics, can realize long-acting administration, improve patient compliance, and shows excellent effects in improving blood glucose control, promoting weight loss, and improving blood lipid level.

This invention relates to nutritional compositions comprising at least one fucosylated oligosaccharide, preferably 2FL, for use in enhancing pancreatic development and / or pancreatic maturation in infants, and / or improving insulin biosynthesis, and / or preventing metabolic disorders or associated diseases, and / or managing glucose during nutritional intervention or later in life. The composition may be an infant formula. The composition may also comprise at least one N-acetylated oligosaccharide, preferably LnNT.

Aspects of the present disclosure include methods for treating a subject having a metabolic disorder by neuromodulation. Methods according to certain embodiments include applying electrical stimulation to the spinal cord of a subject (e.g., a subject diagnosed as having or determined to have diabetes or prediabetes) in a manner sufficient to treat at least one symptom of the metabolic disorder in the subject. In some embodiments, neuromodulation is sufficient to treat one or more symptoms of diabetes or prediabetes such as fasting plasma glucose concentration, non-fasting plasma glucose concentration, elevated hbA1c, glucose tolerance and insulin secretion by the subject. Systems having one or more electrodes configured for applying electrical stimulation to the spinal cord of the subject suitable for practicing the subject methods are also described.

Methods of predicting insulin resistance in a subject are provided. The methods include measuring interstitial fluid glucose in the subject over a period of time to obtain a plurality of glucose values (G(tn)); fitting the measured plurality of glucose values (G(tn)) to a glucose-insulin response model to calculate a plurality of subject-specific parameters, the glucose-insulin response model comprising a modified Lotka-Volterra system of equations for the glucose-insulin response pair (G(t), I(t)); and comparing at least one of the calculated subject-specific parameters to a set threshold value to predict insulin resistance in the subject. Systems for predicting insulin resistance in a subject are also provided. The systems include a continuous glucose monitoring (CGM) sensor and a computation device.

The application discloses a uORF element for regulating chicken insulin receptor expression and application thereof, belongs to the field of molecular biology and genetic engineering, and the nucleotide sequence of the uORF element is shown in any one of SEQ ID NO. 1-2; the application comprises any one of the following: (1) regulating the expression of firefly luciferase in eukaryotic cells; the eukaryotic cells are chicken embryo fibroblasts and chicken preadipocytes; (2) being applied to genetic breeding of chickens, and the genetic breeding is breeding of meat chickens with reduced insulin resistance; (3) application in preparation of a reagent for regulating the expression of chicken insulin receptors. The application can regulate the expression level of INSR, improve insulin sensitivity, and provide material support for research on the mechanism of insulin in regulating blood glucose.

A skin contact sensor 100 for detecting a biomarker in the interstitial fluid of a user such as a subject’s glucose or hydration levels. The sensor comprises a reusable electronics part and a disposable medical patch. The medical patch comprises a substrate 40 with a plurality of electrodes 60, conductive elements 70 (like tracks) and a contact interface 80. The substrate 40 may have a support member (90, figure 4c) and the contact interface 80 may be non-integral to the substrate 40. The reusable electronics are electrically connected to the medical patch via the contact interface 80 by an electrical connector (30, figure 4c) and removably secured to the medical patch by an adhesive such as double-sided tape. Electrical contact between the electrodes 60 and patient’s skin is provided by a conductive gel which also serves as a medium into which interstitial fluid is extracted during use and can also contain enzymes to aid in target detection. [Figure 1a.]

A series of pharmaceutical compositions containing polypeptide dual agonist compounds and pharmaceutically acceptable salts thereof, wherein same have dual agonist effects on a human glucagon-like peptide-1 (GLP-1) receptor and a human blood glucose-dependent insulinotropic polypeptide (GIP) receptor, and can be used for treating non-insulin-dependent diabetes, insulin-dependent diabetes, obesity and other related diseases.

A method for managing glucose levels of a patient under the supervision of a healthcare professional (HCP). The method includes obtaining patient information for the patient, the patient information comprising patient medication data, patient monitoring data, and patient characteristic data. The method also includes creating a patient risk profile based on the patient information. The method also includes determining a likelihood that the patient will experience hyperglycemic effects based on the patient risk profile. The method also includes determining an optimum treatment plan for the patient based on the patient risk profile and the likelihood that the patient will experience hyperglycemic effects. The method also includes executing the optimum treatment plan.

This invention provides a method for determining the biological age, risk of death, and / or probability of healthy lifespan of a dog; the method comprising: a) determining the biological age, risk of death, and / or probability of healthy lifespan of a dog using the levels of one or more biomarkers selected from one or more samples obtained from the dog, wherein the one or more biomarkers are selected from white blood cell count, serum albumin, serum alkaline phosphatase, serum creatine kinase, hemoglobin, hematocrit, mean corpuscular hemoglobin, serum glucose, mean corpuscular volume, serum globulin, serum calcium, platelet count, and / or red blood cell count; and b) determining the biological age, risk of death, and / or probability of healthy lifespan of a dog using DNA methylation profiles from the dog.

Provided in this disclosure is a method for treating fatty liver and / or hepatic fibrosis by administering a combination of a GLP-1 receptor agonist and bempedoic acid. Also provided in this disclosure is a method for modulating target blood glucose control, hemoglobin A1C levels, body weight, systolic and / or diastolic blood pressure, hepatic fat, ballooning hepatocytes, and / or lobular inflammation by administering a combination of a GLP-1 receptor agonist and bempedoic acid.

This invention relates to the field of biomedical technology, specifically to a drug for treating and preventing metabolic obesity caused by a high-fat diet. This invention provides a method to reduce... C2orf74 The use of compositions that reduce gene expression levels in the preparation of medicaments for the prevention and / or treatment of obesity, by utilizing the reduction of gene expression levels. C2orf74 In situ injection of a combination of gene expression levels into the testes of animals can prevent and treat obesity caused by a high-fat diet. Specifically, it can alleviate the obesity phenotype caused by a high-fat diet, including reducing weight gain, reducing fat accumulation, lowering serum triglyceride and cholesterol levels, improving blood glucose regulation and enhancing insulin sensitivity; and reducing the degree of fatty liver degeneration.

This invention provides a physiological age prediction model that predicts the physiological age of a subject by detecting physical examination indicators. These indicators include measurements of blood cells, glucose metabolism, tumor markers, urine components, anthropometric measurements, lipids, blood components, and tissue function. Preferably, these indicators include one or more selected from the following: glomerular filtration rate (eGFR), cystatin C, serum creatinine (SCr), blood urea nitrogen (BUN), timed up and go, light reaction time, fasting blood glucose (FBG), insulin-like growth factor (IGF), superoxide dismutase (SOD), insulin (INS), albumin (Alb), alkaline phosphatase (ALP), folic acid, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and high-sensitivity C-reactive protein (hs-CRP). More preferably, all of the aforementioned physical examination indicators are included. This invention also provides a physiological age prediction device applying the above-mentioned physiological age prediction model and a computer storage medium.